The cost of insulin in syringe pens in Russia may increase by a third. The Federal Antimonopoly Service agreed to increase the marginal price (by 5.5-28%) due to rising production costs. According to Kommersant, the Russian pharmaceutical companies Geropharm and Medsintez, as well as the Danish Novo Nordisk, asked to increase the marginal price.

Geropharm CEO Petr Rodionov told the publication that the company plans to re-register prices for most insulin positions. For some of them, growth will not exceed the level of inflation, that is, by 4-5%. Rodionov added that prices are being reviewed for the first time in several years: during this time, manufacturers have increased costs, and since the end of February, logistics costs have increased further.

We are talking about the forms of insulin lispro, biphasic insulin aspart and biphasic human genetically engineered insulin. After re-registration, the maximum price for Geropharm insulin lispro in syringe pens will reach almost 1.6 thousand rubles per pack and will exceed the cost of the original from Eli Lilly by 11%.

Now the maximum cost of insulin in syringe pens will be higher than in other types - cartridges or vials. Previously, the prices did not differ. The price of insulin lispro in syringe pens from Geropharm will be 10.5% higher.